- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06150664
En fase 1 af CTX-8371 hos patienter med avancerede maligniteter
En fase 1, open-label, multipel-stigende dosis undersøgelse af sikkerheden og tolerabiliteten af CTX-8371 hos patienter med avancerede maligniteter
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This Phase 1, open-label, first-in-human study will evaluate the safety, tolerability, immunogenicity, and pharmacokinetic profile of CTX-8371 monotherapy. Preliminary anti-tumor activity of CTX-8371 will also be assessed. The study will be conducted in 2 cohorts: Dose escalation and Dose expansion. The Dose Escalation Cohort will utilize a 3+3 design to evaluate five dose levels (0.1-10.0 mg/kg) of CTX-8371 given as an IV infusion once every 2 weeks. Patients in the Dose Expansion Cohort will receive CTX-8371 as an IV infusion at 3.0 mg/kg or 10.0 mg/kg at a 1:1 allocation.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Natalie Warholic
- Telefonnummer: 617-500-8099
- E-mail: CTX-8371-001@compasstherapeutics.com
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- Rekruttering
- University of Alabama
-
Ledende efterforsker:
- Lauren Shea, MD
-
Kontakt:
- Diana Avery
- Telefonnummer: 205-957-7182
- E-mail: dinaavery@uabmc.edu
-
-
California
-
Palo Alto, California, Forenede Stater, 94304
- Rekruttering
- Stanford Cancer Institute
-
Ledende efterforsker:
- Ranjana Advani, MD
-
Kontakt:
- Anthony Yu
- Telefonnummer: 650-498-5964
- E-mail: Anthyu20@stanford.edu
-
-
Florida
-
Margate, Florida, Forenede Stater, 33063
- Trukket tilbage
- D&H Cancer Research Center
-
Orlando, Florida, Forenede Stater, 32827
- Rekruttering
- Florida Cancer Specialists - Lake Nona
-
Ledende efterforsker:
- Cesar Perez Batista, MD
-
Kontakt:
- Elizabeth Gilmore
- Telefonnummer: 904-380-2410
- E-mail: elizabeth.griffith@scri.com
-
Sarasota, Florida, Forenede Stater, 34236
- Rekruttering
- Florida Cancer Specialists - Sarasota
-
Ledende efterforsker:
- Judy Wang, MD
-
-
Georgia
-
Athens, Georgia, Forenede Stater, 30607
- Rekruttering
- University Cancer & Blood Center
-
Kontakt:
- Pope, RN, OCN, CCRC
- Telefonnummer: x8235 706-353-2990
- E-mail: npope@universitycancer.com
-
Ledende efterforsker:
- Frederick Flynt, MD, FACP
-
-
Indiana
-
Fort Wayne, Indiana, Forenede Stater, 46804
- Rekruttering
- Fort Wayne Medical Oncology and Hematology
-
Ledende efterforsker:
- Sunil Babu, MD
-
Kontakt:
- Andrea Vazquez
- Telefonnummer: 42165 260-436-0800
- E-mail: andrea.vasquez@aoncology.com
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Dana-Farber Cancer Institute
-
Kontakt:
- Kailene Sullivan, RN
- Telefonnummer: 617-632-3482
- E-mail: Kailene_sullivan@dfci.harvard.edu
-
Ledende efterforsker:
- Patrick Ott, MD, PhD
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Beth Israel Deaconess Medical Center
-
Kontakt:
- Susan Gotthardt, RN
- E-mail: sgotthar@bidmc.harvard.edu
-
Ledende efterforsker:
- Hollis Viray, MD
-
-
New York
-
Buffalo, New York, Forenede Stater, 14263
- Rekruttering
- Roswell Park Cancer Institute
-
Kontakt:
- ASKRPCI
- Telefonnummer: 800-767-9355
- E-mail: askroswell@roswellpark.org
-
Ledende efterforsker:
- Benjamin Switzer, DO
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Tennessee Oncology
-
Kontakt:
- Lauren Carey
- E-mail: lcary@tnonc.com
-
Ledende efterforsker:
- Jeff Russell, MD
-
-
Washington
-
Spokane, Washington, Forenede Stater, 99208
- Rekruttering
- Summit Cancer Center
-
Ledende efterforsker:
- Arvind Chaudhry, MD
-
Kontakt:
- Monika Chaudhry
- Telefonnummer: 509-462-2273 opt 7
- E-mail: mchaudhry@summitcancercenters.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Age 18 years or older
-
Patients must have a histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic disease that is relapsed/refractory to standard therapy or for which no effective standard therapy is available, including
-
Malignant Melanoma (MM)
- Patients who have progressed after a minimum of 2 doses of a PD-1/PD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1/PD-L1 blocking antibody
- Patients must have had prior testing for BRAF V600 mutations. Patients with BRAF V600 activating mutation must have received prior therapy with a BRAF/MEK inhibitor
- Uveal and mucosal melanoma are excluded
-
Head and Neck squamous cell carcinoma (HNSCC)
- HNSCC of oral cavity, oropharynx, hypopharynx, or larynx
- Patients who have progressed after a minimum of 2 doses of a PD-1/PD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1/PD-L1 blocking antibody
- Patients must have received prior treatment with platinum-based chemotherapy
-
Non-Small Cell Lung Cancer (NSCLC)
- Patients who have progressed after a minimum of 2 doses of a PD-1/PD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1/PD-L1 blocking antibody
- Patients must have received prior treatment with platinum-based chemotherapy
-
Triple Negative Breast Cancer (TNBC)
- ER/PR and HER2 status should be defined by ASCO/CAP guidelines (JCO Allison et al 2020)
- Patients with HER2-low cancers (HER2 IHC 1+ or 2+/ISH negative) are excluded
- Patients must have received prior sacituzumab govitecan and if PD-L1 ≥10% by CPS pembrolizumab with chemotherapy
-
Classical Hodgkin Lymphoma (HL)
- Patients must have received at least two prior systemic therapies including brentuximab vedotin (if eligible) and a prior PD-1 inhibitor
- Patients must have experienced less than a CR (according to Lugano criteria) to anti- PD-1 treatment
-
(Cohort 2 Dose Expansion): Non-Small Cell Lung Cancer (NSCLC)
- Patients who have progressed after a minimum of 2 doses of a PD-1/PD-L1 treatment
- Patients must have received prior treatment with platinum-based chemotherapy
-
(Cohort 2 Dose Expansion) Triple Negative Breast Cancer (TNBC)
- ER/PR and HER2 status should be defined by ASCO/CAP guidelines (JCO Allison et al 2020)
- Patients must have received prior sacituzumab govitecan and if PD-L1 ≥10% by CPS pembrolizumab with chemotherapy
- Patients with HER2-low tumors (HER2 IHC 1+ or 2+/ISH negative) need to have received fam-trastuzumab deruxtecan (Enhertu)
-
(Cohort 2 Dose Expansion) Classical Hodgkin's Lymphoma (HL)
- Patients must have received at least two prior systemic therapies including brentuximab vedotin (if eligible) and a prior PD-1 inhibitor.
- Patients must have received at least 12 weeks of treatment with a PD-1/PD-L1 inhibitor as a monotherapy or in combination and had at least stable disease or progressive disease (PD) with overall clinical benefit.
-
-
Patients with NSCLC, MM, TNBC, and HNSCC must have measurable disease per RECIST 1.1. Patients with HL must have at least one measurable lesion > 1.5 cm for nodal, > 1.0 cm for extranodal FDG-avid disease by the Lugano (2014) response criteria. Tumor sites that are considered measurable must not have received prior radiation
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Adequate bone marrow function defined by absolute neutrophil (ANC) of ≥ 1.5×109/L, platelet count of ≥ 100.0×109/L, and hemoglobin of ≥ 9.0 g/dL (with or without transfusion)
a. (Cohort 2 Dose Expansion) Adequate bone marrow function defined by absolute neutrophil (ANC) of ≥ 1.5×109/L, platelet count of ≥ 100.0×109/L, and hemoglobin of ≥ 9.0 g/dL (with or without transfusion) within 2 weeks from the first dose of CTX-8371.
- Blood transfusion is not allowed within 2 weeks from the first dose of CTX-8371
-
Adequate hepatic function defined as serum total bilirubin ≤ 1.5 × ULN, AST/ALT ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases)
-
Adequate renal function defined as creatinine clearance ≥ 30mL/min by Cockcroft-Gault equation
-
Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or commits to use 2 acceptable forms of birth control (defined as the use of an intrauterine device (IUD), a barrier method with spermicide, condoms, any form of hormonal contraceptives) or abstinence for the duration of the study and for 4 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment
-
Female patients who are women of childbearing potential (WOCBP) must have a negative serum pregnancy test at Screening within 7 days of dosing with CTX-8371
-
Last dose of previous PD-1 or PD-L1 therapy ≥ 28 days, other anticancer therapy > 21 days (or 2 half-lives for proteins, whichever is longer), radiotherapy >21 days (concurrent localized palliative radiotherapy is allowed during CTX-8371 treatment), or surgical intervention >21 days prior to the first dose of CTX-8371
-
Resolution of all prior anti-cancer therapy toxicities ≤ Grade 2
-
Life expectancy ≥ 12 weeks
-
Capable of understanding and complying with protocol requirements
-
Signed and dated institutional review board (IRB)/independent ethics committee (IEC)-approved informed consent form (ICF) before any protocol-directed screening procedures are performed
Exclusion Criteria:
-
Developed clinically significant adverse reaction to PD-1 or PD-L1 therapy, including immune related adverse reactions, which led to discontinuation of treatment
-
Systemic therapy with immunosuppressive agents within 7 days before the start of CTX-8371 treatment. Topical, intranasal, intraocular, or inhaled corticosteroids and physiologic replacement for patients with adrenal insufficiency are allowed
-
Patient is a pregnant or lactating WOCBP
-
Prior organ transplantation
-
Patients with evidence of active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection. Patients with positive HBsAg and/or detectable HBV DNA are eligible only if adequately controlled on antiviral therapy according to institutional standards and liver function eligibility criteria are also met. HCV patients showing sustained viral response or patients with immunity to HBV infection may enroll.
-
Active autoimmune disease or medical conditions requiring chronic steroid (i.e., > 10 mg/day prednisone or equivalent) or immunosuppressive therapy. Patients with a prior history of autoimmune disease may be eligible following discussion with the Medical Monitor
-
History of primary malignancy other than the malignancy under study will be excluded, except for malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate >90%). Prior malignancy history will be evaluated on a case-by-case basis by the Sponsor Medical Monitor.
-
Symptomatic or uncontrolled central nervous system and brain metastasis or active leptomeningeal disease. Patients with equivocal findings or with confirmed brain metastases are eligible for the study provided that they are asymptomatic and radiologically and neurologically stable without the need for corticosteroid treatment or seizure prophylaxis for ≥4 weeks before the first dose of study drug. Prior treatment with either surgery or radiation is permitted and all patients with a history of CNS or brain lesions require imaging during screening to confirm stability.
-
Other medical condition that in the opinion of the Investigator and/or Sponsor Medical Monitor may interfere with the conduct and/or interpretation of the current study, including:
- Congestive heart failure (> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or clinically significant cardiac arrhythmias
- QTc interval (using Fridericia correction calculation) > 480 msec
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Dose Escalation Cohort 1
Escalating doses of CTX-8371 |
Intravenous (IV) infusion every two weeks. |
|
Eksperimentel: Dose Expansion Cohort 2
Two CTX-8371 dose groups (3.0 mg/kg and 10.0 mg/kg) in three tumor type subgroups (NSCLC, TNBC, and HL) |
Intravenous (IV) infusion every two weeks. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Kohorte 1: Fastlæg dosis/doser af CTX-8371, der skal undersøges yderligere i Kohorte 2 og i fase 2-studier
Tidsramme: Fra første dosis af CTX-8371 (Cyklus 1 dag 1, cyklus = 2 uger) indtil 30 dage efter sidste dosis af CTX-8371 (gennemsnitligt 6 måneder)
|
Fra første dosis af CTX-8371 (Cyklus 1 dag 1, cyklus = 2 uger) indtil 30 dage efter sidste dosis af CTX-8371 (gennemsnitligt 6 måneder)
|
|
|
Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371
Tidsramme: From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-8371, average of 6 months
|
Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities |
From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-8371, average of 6 months
|
|
Cohort 2: Evaluate the safety and tolerability of CTX-8371 at 3.0 mg/kg and 10.0 mg/kg
Tidsramme: From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-8371 (up to 2 years)
|
Incidence of treatment-emergent adverse events (TEAEs) |
From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-8371 (up to 2 years)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Kohorte 1 og 2: Objektiv responsrate (ORR) (procentdel af deltagere med objektiv respons) i henhold til Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Tidsramme: Fra baseline indtil bekræftet sygdomsprogression (op til 2 år)
|
Fra baseline indtil bekræftet sygdomsprogression (op til 2 år)
|
|
|
Kohorte 1 og 2: Responsvarighed (DOR) ifølge Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Tidsramme: Fra datoen for første bekræftede CR eller PR indtil første dato for tilbagevendende eller progressiv sygdom (op til 2 år)
|
Fra datoen for første bekræftede CR eller PR indtil første dato for tilbagevendende eller progressiv sygdom (op til 2 år)
|
|
|
Kohorte 1 og 2: Progressionsfri overlevelse (PFS) ifølge Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Tidsramme: Fra første dosis af CTX-8371 (cyklus 1 dag 1, cyklus = 2 uger) indtil sygdomsprogression eller død, alt efter hvad der indtræffer først (op til 2 år)
|
Fra første dosis af CTX-8371 (cyklus 1 dag 1, cyklus = 2 uger) indtil sygdomsprogression eller død, alt efter hvad der indtræffer først (op til 2 år)
|
|
|
Kohorte 1 og 2: Overlevelse (OS) for CTX-8371
Tidsramme: Fra første dosis af CTX-8371 (cyklus 1 dag 1, cyklus = 2 uger) indtil død (op til 2 år)
|
Fra første dosis af CTX-8371 (cyklus 1 dag 1, cyklus = 2 uger) indtil død (op til 2 år)
|
|
|
Kohorte 1 og 2: Maksimal serumkoncentration (Cmax) af CTX-8371
Tidsramme: Fra første dosis af CTX-8371 (cyklus 1 dag 1, cyklus = 2 uger) indtil behandlingen afbrydes
|
Fra første dosis af CTX-8371 (cyklus 1 dag 1, cyklus = 2 uger) indtil behandlingen afbrydes
|
|
|
Kohorte 1 og 2: Tidspunkt for maksimal observeret serumkoncentration (Tmax) af CTX-8371
Tidsramme: Fra første dosis af CTX-8371 (Cykel 1 Dag 1, Cykel = 2 uger) indtil behandlingsophør
|
Fra første dosis af CTX-8371 (Cykel 1 Dag 1, Cykel = 2 uger) indtil behandlingsophør
|
|
|
Kohorte 1 og 2: Bundkoncentration (Ctrough) af CTX-8371 i serum
Tidsramme: Fra første dosis af CTX-8371 (Cykel 1 dag 1, Cykel = 2 uger) indtil behandlingsophør
|
Fra første dosis af CTX-8371 (Cykel 1 dag 1, Cykel = 2 uger) indtil behandlingsophør
|
|
|
Kohorte 1 og 2: Areal under serumkoncentrationen af CTX-8371 versus tidskurve (AUC) for CTX-8371
Tidsramme: Fra første dosis af CTX-8371 (Cykel 1 Dag 1, Cyklus = 2 uger) indtil behandlingsophør
|
Fra første dosis af CTX-8371 (Cykel 1 Dag 1, Cyklus = 2 uger) indtil behandlingsophør
|
|
|
Kohorte 1 og 2: Clearance (CL) af serumkoncentrationer af CTX-8371
Tidsramme: Fra første dosis CTX-8371 (Cykel 1 Dag 1, Cykel = 2 uger) indtil behandlingsophør
|
Fra første dosis CTX-8371 (Cykel 1 Dag 1, Cykel = 2 uger) indtil behandlingsophør
|
|
|
Kohorte 1 og 2: Distributionsvolumen (Vd) for serumkoncentrationer af CTX-8371
Tidsramme: Fra første dosis af CTX-8371 (Cykel 1 dag 1, Cykel = 2 uger) indtil behandlingsophør
|
Fra første dosis af CTX-8371 (Cykel 1 dag 1, Cykel = 2 uger) indtil behandlingsophør
|
|
|
Kohorte 1 og 2: Halveringstid (t1/2) for serumkoncentrationer af CTX-8371
Tidsramme: Fra første dosis af CTX-8371 (Cyklus 1 Dag 1, Cyklus = 2 uger) indtil behandlingsophør
|
Fra første dosis af CTX-8371 (Cyklus 1 Dag 1, Cyklus = 2 uger) indtil behandlingsophør
|
|
|
Kohorte 1 og 2: Dosisrespons for CTX-8371
Tidsramme: Fra første dosis af CTX-8371 (Cykel 1 dag 1, Cykel = 2 uger) indtil behandlingsophør
|
Fra første dosis af CTX-8371 (Cykel 1 dag 1, Cykel = 2 uger) indtil behandlingsophør
|
|
|
Kohorte 1 og 2: Objektiv responsrate (ORR) (Procentdel af deltagere med objektiv respons) i henhold til Lugano (2014)
Tidsramme: Baseline indtil bekræftet sygdomsprogression (op til 2 år)
|
Baseline indtil bekræftet sygdomsprogression (op til 2 år)
|
|
|
Kohorte 1 og 2: Varighed af respons (DOR) ifølge Lugano (2014)
Tidsramme: Fra datoen for første bekræftede CR eller PR indtil den første dato for tilbagevendende eller progressiv sygdom (op til 2 år)
|
Fra datoen for første bekræftede CR eller PR indtil den første dato for tilbagevendende eller progressiv sygdom (op til 2 år)
|
|
|
Kohorte 1 og 2: Progressionfri overlevelse (PFS) ifølge Lugano (2014)
Tidsramme: Fra første dosis af CTX-8371 (Cykel 1 dag 1, Cykel = 2 uger) indtil sygdomsprogression eller død, alt efter hvad der indtræffer først
|
Fra første dosis af CTX-8371 (Cykel 1 dag 1, Cykel = 2 uger) indtil sygdomsprogression eller død, alt efter hvad der indtræffer først
|
|
|
Cohort 1 and 2: Assess the immunogenicity of CTX-8371
Tidsramme: From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until end of treatment visit
|
Screen for the presence and development of antibodies against CTX-8371 |
From first dose of CTX-8371 (Cycle 1 Day 1, Cycle = 2 weeks) until end of treatment visit
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Sygdomme i immunsystemet
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Lungesygdomme
- Neoplasmer i hoved og hals
- Neoplasmer, kirtel og epitel
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Lungeneoplasmer
- Hudsygdomme
- Brystsygdomme
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Karcinom
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Lymfom
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Neuroendokrine tumorer
- Nevi og melanomer
- Neoplasmer i huden
- Karcinom, pladecelle
- Brystneoplasmer
- Hud- og bindevævssygdomme
- Hemiske og lymfatiske sygdomme
- Planocellulært karcinom i hoved og hals
- Karcinom, ikke-småcellet lunge
- Melanom
- Hodgkins sygdom
- Tredobbelt negative brystneoplasmer
Andre undersøgelses-id-numre
- CTX-8371-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .